Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
The economic and fiscal policy guidelines that the government will adopt at the end of June will not carry the words “an annual NHI price revision” in its reform plan for Japan’s pharmaceutical arena - a topic that has caused…
To read the full story
Related Article
COMMENTARY
- Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
August 3, 2026
- Rare Cancer Case Raises New Questions about AAV Gene Therapy Safety
July 27, 2026
- A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
- DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
July 6, 2026
- New Generic Listings Plunge, Industry Heads for a Shakeout
July 1, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…